# Protocol Analysis: PBCAR20A-01

### Q: What is the study design of PBCAR20A-01? Describe Phase 1 and Phase 2a components.

**A:** 

### Q: What are the planned dose levels and cohorts for the study?

**A:** 

### Q: What are the treatment arms and population flags defined in the study?

**A:** 

### Q: What are the primary and secondary endpoints, especially those related to safety (CRS, ICANS)?

**A:** 

### Q: Summarize the key inclusion and exclusion criteria that define the Safety and Efficacy populations.

**A:** 
